Frenelle Pharma, a groundbreaking portfolio of companies leveraging FarosTM, our proprietary long-acting injectable technology, is proud to announce its official launch. Building on the success of ...

Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver ...